chemieunternehmen.com

Evotec AG today announced that CHDI Foundation, Inc. has extended and expanded its collaboration with Evotec through to August 2018. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-chdi-foundation-expand-ongoing-collaboration-to-fight-huntingtons-disease-using-evotecs-expanded-capabilities-and-footprint-5305

Evotec AG today reported financial results and corporate updates for the first half of 2015. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-first-half-of-2015-5303

Evotec AG and Apeiron Biologics AG, a biotech company with a focus on immunological approaches to treat cancer, today announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-apeiron-biologics-and-sanofi-jointly-develop-novel-small-molecule-based-cancer-immunotherapies-5301

Evotec AG and Sanofi today announced a strategic collaboration in the field of diabetes. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/sanofi-and-evotec-align-forces-to-develop-next-generation-therapies-in-diabetes-5299

Evotec AG today announced that it has become part of a research initiative between a newly established for-profit company of the Gladstone Institutes called Cure Network Ventures, Inc. and Dolby Family Ventures. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-innovative-research-initiative-with-gladstone-institutes-and-dolby-family-ventures-in-alzheimers-disease-5295

Evotec AG  was updated today by its partner Roche on the initial results of the Phase IIb trial with Sembragiline, a MAO-B inhibitor for the treatment of Alzheimer’s disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotecs-partner-roche-provides-initial-update-from-phase-iib-trial-in-alzheimers-disease-5293

– VERY STRONG START TO 2015: 22% GROWTH OF GROUP REVENUES, MAINLY DRIVEN BY EVT EXECUTE – MAJOR MULTI-COMPONENT STRATEGIC ALLIANCE WITH SANOFI CLOSED- FULL-YEAR REVENUE GUIDANCE RAISED   Hamburg, Germany – 12 May 2015: … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-first-quarter-2015-5285